ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV)-optimized cyclophilin inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE